CLINICAL_TRIALS
trial_result
· 2014-11-24
Clinical Trial Update: Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia [Phase 3]
Summary
Phase 3 trial comparing Ofatumumab to physician's choice in bulky, fludarabine-refractory chronic lymphocytic leukemia has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Leukaemia | Phase 3 | Status: COMPLETED | Results posted: 2014-11-24